Skip to main content

Table 1 Characteristics of cases and controls

From: Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case–control study

 

Laboratory confirmed influenza cases

Test-negative controls

 
 

n (%)

n (%)

p-value

Total

303 (100)

286 (100)

 

Age groups (years)

  

0.004

  < 5

10 (3.3)

9 (3.1)

 

  5 - 14

38 (12.4)

19 (6.6)

 

  15 - 44

174 (57.4)

151 (52.8)

 

  45 - 64

65 (21.5)

69 (24.1)

 

  65 - 79

13 (4.3)

26 (9.1)

 

  ≥ 80

3 (1.0)

12 (4.2)

 

Sex

  

0.387

  Male

146 (48.2)

148 (51.7)

 

  Female

157 (51.8)

138 (48.3)

 

Residence

  

0.943

  Rural

43 (14.2)

40 (14.0)

 

  Urban

260 (85.9)

246 (86.0)

 

Major chronic conditions

  

0.005

  0

232 (76.5)

199 (69.6)

 

  1

59 (19.5)

56 (19.6)

 

  > 1

12 (4.0)

31 (10.8)

 

Outpatient visits in the previous year

  

0.047

  0

53 (17.5)

33 (11.5)

 

  1 to 4

134 (44.2)

120 (42.0)

 

  > 4

116 (38.3)

133 (46.5)

 

Health care setting

  

<0.001

  Primary health care

290 (95.7)

240 (83.9)

 

  Hospital

13 (4.3)

46 (16.1)

 

Period

  

<0.001

  Week 43 to 46/2010

5 (1.7)

40 (14.0)

 

  Week 47 to 50/2010

6 (1.9)

18 (6.3)

 

  Week 51/2010 to 2/2011

192 (63.4)

101 (35.3)

 

  Week 3 to 6/2011

81 (26.7)

95 (33.2)

 

  Week 7 to 12/2011

19 (6.3)

32 (11.2)

 

Delay between symptom onset and swabbing

  

0.118

  ≤4 days

297 (98.0)

274 (95.8)

 

  >4 days

6 (2.0)

12 (4.2)

 

Pandemic influenza vaccine 2009-2010

  

0.001

  No

297 (98.0)

260 (90.9)

 

  Yes

6 (2.0)

26 (9.1)

 

Seasonal influenza vaccine 2010-2011

  

<0.001

  No

290 (95.7)

241 (84.3)

 

  Yes

13 (4.3)

45 (15.7)